A research group led by Drs.Shusuke Tada and Takashi Tsuyama at the Department of Molecular Biology, Faculty of Pharmaceutical Sciences, Toho University, has demonstrated that overexpression of Cdc10-dependent transcript 1 (CDT1), a key regulator of DNA replication initiation, induces DNA damage and potentially results in genetic mutations.
Although previous studies have linked CDT1 overexpression to cellular transformation and tumorigenesis, the underlying mechanism has remained unclear.
The findings not only reveal the impact of CDT1 overexpression on DNA replication progression post initiation but also provide molecular insights into its role in cancer development.
This research was published online in the journal FEBS Open Bio.
During the initiation of DNA replication, the mini-chromosome maintenance (MCM) complex, a DNA helicase, binds to replication origins and promotes replication fork progression.
The replication fork may stall due to various factors, and prolonged stalling may cause DNA breaks, resulting in cell death or cancer.
Although CDT1 plays an essential role in loading the MCM complex onto replication origins, its overexpression has been implicated in oncogenesis.
However, the underlying mechanism remains unclear.
By analysing various CDT1 mutants and establishing cell lines with inducible CDT1 overexpression, the research group demonstrated that CDT1 overexpression suppresses replication fork progression and induces DNA damage.
These findings reveal a novel function of CDT1 in DNA replication and provide molecular insights into the oncogenic process triggered by its overexpression.
Key Findings:
Source: Toho University
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.